FDA approves Qelbree, a Non-stimulant Treatment for ADHD
The FDA has approved Qelbree (SPN-812), for children aged 6 to 17 years with attention deficit hyperactivity disorder (ADHD)....
MDforLives
Exon-skipping drug approved for the third subtype of Duchenne muscular dystrophy
Discovering treatments for Duchenne muscular dystrophy has been difficult because the disease is a result of a wide variety...
Circadian Clock Protein CRY1 – The Novel Target for Prostate Cancer
Prostate cancer is one of the most common cancers and a second leading cause of cancer death in American...
GLP-1 receptor agonists and/or DPP4 inhibitors: Diabetes drugs may lower the risk of Parkinson’s disease
Parkinson’s disease, the most common neurodegenerative movement disorder has growing prevalence with the age. Due to increasing life expectancy...
CAR-T Therapy Approved for B-Cell Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma treatment traditionally relied on chemotherapy, radiation, and bone marrow transplant. More recently, immuno-oncology treatments have come to...
Bispecific antibodies are progressing in cancer clinical trials
The human immune system makes antibodies that bind to the same antigen with both of their variable regions, or...
A new device for mild sleep apnea
Most non-surgical options for managing mild sleep apnea simply keep the airway open while the individual sleeps. A new...
CRISPR-Based Diagnostics on the Rise
In 2020, the Nobel Prize in Chemistry was awarded for “the development of a method for genome editing” based...
Can the Stages of Chronic Kidney Disease (CKD) be Reversed?
Chronic kidney disease (CKD), a global public issue is associated with substantial morbidity and mortality. In the past few...
Phase III trial beginning for a Charcot-Marie-Tooth disease therapy
An investigational therapy for Charcot-Marie-Tooth (CMT) disease is beginning its second Phase III trial. The therapy, called PXT3003, is...